German radiopharmaceutical firm ITM Isotope Technologies Munich SE (ITM) highlighted its lutetium-177 (Lu-177) supply deal with Novartis in the wake of the U.S. Food and Drug Administration's (FDA) approval of the company's Pluvicto radioligand therapy.
The FDA approved Pluvicto (Lu-177 PSMA-617) on March 23 for the treatment of patients with metastatic prostate cancer that has proven resistant to treatments such as taxane-based chemotherapy or androgen receptor therapy.
ITM has been supplying Novartis with Lu-177 since the companies inked a supply deal in 2020, and said it is poised to support the scalability and security of supply of the radioisotope for patients worldwide.
